Spinal bulbar muscular atrophy (SBMA) is a motor neuron disease caused by toxic gain of function of the androgen receptor (AR). Previously, we found that co-regulator binding through the activation function-2 (AF2) domain of AR is essential for pathogenesis, suggesting that AF2 may be a potential drug target for selective modulation of toxic AR activity. We screened previously identified AF2 modulators for their ability to rescue toxicity in a Drosophila model of SBMA. We identified two compounds, tolfenamic acid (TA) and 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole (MEPB), as top candidates for rescuing lethality, locomotor function and neuromuscular junction defects in SBMA flies. Pharmacokinetic analyses in mice revealed a more favorable bioavailability and tissue retention of MEPB compared with TA in muscle, brain and spinal cord. In a preclinical trial in a new mouse model of SBMA, MEPB treatment yielded a dose-dependent rescue from loss of body weight, rotarod activity and grip strength. In addition, MEPB ameliorated neuronal loss, neurogenic atrophy and testicular atrophy, validating AF2 modulation as a potent androgen-sparing strategy for SBMA therapy.
SBMA, or Kennedy's disease, is a progressive neurodegenerative disease that affects approximately 1 in 40,000 men worldwide 1 ; however, this number is likely underestimated as a result of common misdiagnoses (for example, limb girdle muscular dystrophy and amyotrophic lateral sclerosis (ALS)) 2 . Although SBMA is not typically fatal, quality of life is profoundly affected, as patients experience bulbar dysfunction, limb weakness, loss of ambulation and partial androgen insensitivity that often leads to feminization, testicular atrophy and fertility problems. Neuromuscular symptoms generally first appear as muscle spasms and weakness in the extremities, mouth and throat, which progress to muscle wasting as a result of the loss of motor neurons. There is no cure for SBMA and treatment is symptomatic, usually entailing physical therapy and rehabilitation. Patients with SBMA frequently become confined to a wheelchair later in life and require assistance with common daily tasks, such as eating 2 .
SBMA results from a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene, resulting in an expanded polyglutamine (polyQ) tract within the protein 3 . In healthy, unaffected males, AR typically contains 15-37 CAG repeats, whereas the presence of 40 or more CAG repeats results in the manifestation of disease 4, 5 . However, the presence of a polyQ expansion in the AR by itself is not sufficient to drive disease pathology, as evidenced by the absence of SBMAassociated symptoms in female carriers 6 . Specifically, androgen stimulation of the AR, typically by the cognate ligands testosterone or dihydrotestosterone (DHT), has been extensively characterized to be required for induction of polyQ-expanded AR-mediated toxicity 7 , indicating that activation of the downstream AR signaling pathway via receptor-ligand interaction is a necessary first step to drive neurodegeneration.
In a previous study using a Drosophila model of SBMA, we found that two additional native functions of the AR were required to perpetuate disease: interaction between the AR and its transcriptional target genes through the AR DNA-binding domain (DBD) and interaction between the AR and transcriptional co-regulators through the AR activation function-2 (AF2) domain 8 . Expression of a polyQ-expanded, human AR transgene containing a point mutation rendering the DBD inactive (A574D substitution) abolished DHT-dependent degeneration, suggesting that the SBMA degenerative phenotype is a result of a change in polyQ-expanded AR-mediated transcriptional activity. The transcriptional activity of AR is modified by binding of various co-regulatory proteins, which can serve as coactivators or co-repressors of AR target genes 9 . The AF2 domain is a regulatory pocket located in the ligand binding domain (LBD), which becomes accessible to binding of coregulator proteins containing LXXLL or FXXLF motifs, following androgen stimulation 10 . Expression of polyQ-expanded AR containing a point mutation resulting in a K720A substitution, which inhibits binding of LXXLL-bearing co-regulators and attenuates binding of FXXLF-bearing co-regulators, partially rescued DHT-dependent degeneration in the fly eye 8 . Expression of polyQ-expanded AR containing an E897K substitution, which inhibits binding of co-regulators bearing either LXXLL or FXXLF motifs, fully rescued DHT-induced degeneration, demonstrating a pivotal role for co-regulators in SBMAassociated toxicity 8 .
Studies in mouse models of SBMA have used chemical and physical castration as a method for rescuing the SBMA degenerative phenotype [11] [12] [13] . Consequently, androgen antagonists and drugs that promote AR degradation have been suggested as therapeutic treatment of SBMA 14, 15 . In a phase II placebo-controlled clinical trial, patients treated with the anti-androgen leuprorelin for 144 weeks exhibited significantly diminished serum levels of creatine kinase, significantly improved functional scores and significantly better swallowing parameters than those who received a placebo 16 . More recently, a larger randomized placebo-controlled, multicentric clinical trial of this drug revealed no definite effect on motor functions, although swallowing function improved in a subgroup of patients whose disease duration was less than 10 years 14 . Although an androgen ablation strategy may be effective at reducing SBMAassociated neuromuscular degeneration in patients, long-term, widespread loss of the AR signaling pathway would likely result in severe endocrine disruption, producing multiple adverse side effects and further antagonizing the loss of quality of life (QOL) in patients with SBMA. Alternatively, modulation of native co-regulator-AR interactions with AF2-specific small-molecule compounds such as selective AR modulators (SARMs) holds great promise for a targeted therapeutic approach.
RESULTS

AF2 modulation rescues degeneration in SBMA flies
We compiled a panel of small-molecule compounds that had been identified by in silico or in vitro screening as modulating co-regulator binding to the AR AF2 domain by specifically binding to a proximal regulatory pocket known as the binding function-3 (BF3) domain [17] [18] [19] [20] [21] [22] . Following binding of such compounds to the BF3 domain, a conformational shift occurs in the AF2 domain that modulates the ability of co-regulators bearing FXXLF and LXXLL motifs to bind the AF2 domain (Fig. 1a) . To determine whether such compounds may be advantageous for SBMA therapy, we tested their ability to rescue DHT-induced lethality in flies expressing polyQ-expanded AR in pan-neuronal tissues (ELAV>UAS-AR52Q) or specifically in motor neurons (OK371>UAS-AR52Q) ( Supplementary Fig. 1 and data not shown). TA and MEPB treatment significantly increased SBMA fly viability in a dose-dependent manner (Fig. 1b,c) , similar to the known AR antagonist bicalutamide, whereas an AR-unrelated compound, ibuprofen, did not (Supplementary Fig. 1 ). Consistent with these results, both TA and MEPB significantly restored locomotor function in flies expressing polyQ-expanded AR in motor neurons (OK371>UAS-AR52Q), as measured as increased displacement and velocity of walking in adult flies ( Fig. 1d-f) , to similar levels observed in flies expressing AR variants that modulate co-regulator binding to the AF2 domain (OK371>UAS-AR52Q-K720A and OK371>UAS-AR66Q-E897K). Furthermore, TA and MEPB restored DHT-dependent neuromuscular junction defects in the SBMA larvae of OK371>UAS-AR52Q flies by reducing the prevalence of satellite boutons and preventing the loss of neuromuscular junction branching (Fig. 1g) . These results were corroborated in flies expressing polyQ-expanded AR in the eye (GMR>UAS-AR52Q), in which DHTdependent degeneration was mitigated by TA and MEPB, similar to that of bicalutamide and dimethylcurcumin (Supplementary Fig. 2a ), without reducing monomeric or aggregated forms of AR protein levels ( Supplementary Fig. 2b-e) .
Transgenic male mice carrying full-length human AR with 121 CAG repeats recapitulate SBMA symptoms and pathology Previously reported mouse models of SBMA that exhibit disease-relevant phenotypes express the polyQ-AR transgene at levels severalto-many-fold higher than endogenous AR. For example, the most frequently used mouse model of SBMA 12 expresses exogenous human AR at levels approximately threefold higher than endogenous AR levels ( Supplementary Fig. 3c,d ). Although these prior mouse models of SBMA have been a valuable resource to the research community, we were concerned that high levels of mutant AR expression might mask the therapeutic potential of SARMs. Thus, to evaluate the efficacy of SARM therapy in a mammalian system, we developed an animal model that phenocopies the disease-relevant features of SBMA by expressing physiologically relevant levels of mutant AR. Founder SBMA mice were produced by pronuclear injection of human AR cDNA containing 121 CAG/CAA alternating repeats driven by the pCAGGS (CMV-IE enhancer + chick β-actin) promoter (Supplementary Fig. 3a,b) . We identified one line that expressed the AR transgene in spinal cord and muscle at endogenous levels ( Supplementary Fig. 3c,d ) and used this line for further characterization.
Beginning at approximately 4 weeks of age, male AR121Q mice demonstrated rapid androgen-dependent declines in body weight, rotarod activity, grip strength and survival ( Fig. 2a-d ) when compared with nontransgenic FVB/NJ (NTG) control littermates. Immunohistochemistry using anti-AR, anti-polyQ and anti-ubiquitin revealed the presence of aggregates in the brain, spinal cord and skeletal muscle, but not in the testis or liver, of AR121Q mice (Fig. 2e,f and Supplementary Fig. 3e-g ). These ubiquitin-positive nuclear inclusions also colocalized with polyQ in the spinal cord and skeletal muscle ( Fig. 2g and Supplementary Fig. 3h ). Muscle fiber type switching from glycolytic type II fibers to oxidative type I fibers has recently been characterized as a pathologic hallmark of muscle atrophy in mice and patients with SBMA 23 . Consistent with this characterization, AR121Q mice displayed a marked presence of atrophied skeletal muscle fibers and switching of muscle fibers from glycolytic type II to oxidative type I (Fig. 2h,i) . Furthermore, we observed significantly fewer numbers, but no change in the area of, choline acetyltransferase (ChAT)-positive motor neurons in the anterior horn of the thoracic spinal cord in AR121Q mice compared with NTG controls (Fig. 2j) . Immunofluorescence with antibodies against neuronal cell adhesion molecule (NCAM) and its polysialic acid form (PSA-NCAM), a protein that is known to be upregulated during muscle reinnervation [24] [25] [26] , revealed marked sarcoplasmic stainingof muscle fibers in AR121Q mice, but not in NTG controls (Fig. 2k) , demonstrating ongoing denervation/re-innervation in AR121Q mice. AR121Q mice also exhibited markedly decreased hindlimb muscle mass and increased angular fibers (data not shown). Although centralized nuclei were present in some muscle fibers of AR121Q mice (Fig. 2f) , quantification revealed that less than 3% of fibers in both AR121Q and NTG mice had centralized nuclei, with no difference between the two groups ( Supplementary Fig. 3i ). Together, these data suggest that AR121Q mice exhibit primarily neurogenic rather than myogenic atrophy and weakness.
Finally, we also observed testicular atrophy in the SBMA mice, similar to that described for an AR113Q knock-in mouse model of SBMA (Supplementary Fig. 3j ) 27 . This feature is consistent with the partial androgen insensitivity experienced by patients with SBMA, which manifests as testicular atrophy, gynecomastia and reduction in secondary sexual characteristics, and can impair QOL. The partial androgen insensitivity experienced by SBMA patients is not reversed and may be aggravated by conventional, nonselective androgen ablation.
AF2 modulation improves neurodegenerative outcomes in a pilot study in SBMA mice To ascertain the potential efficacy of AF2 modulation in the SBMA mice, we performed a preclinical pilot assessment of the effects of AF2 modulation on SBMA-associated degeneration in a small cohort of mice. Male SBMA mice were injected intraperitoneally (50 mg/kg body weight, three times per week) with TA, MEPB or vehicle (1% DMSO in corn oil) at 3-8 weeks of age. MEPB treatment significantly improved body weight, rotarod activity and grip strength (Fig. 3a-c) , despite inducing no significant change in survival (Fig. 3d) , and improved gait and hindlimb clasping (Fig. 3e,f) . In addition, the pathologic appearance of skeletal muscle and spinal cord degeneration was qualitatively recovered by MEPB treatment (Fig. 3g,h ). TA treatment did not significantly alter any measurements of SBMA-associated degeneration (Fig. 3) , suggesting that MEPB provides superior therapeutic potential in SBMA mice. Indeed, pharmacokinetic analysis of TA and MEPB in NTG mice revealed marked penetration and, most importantly, duration of MEPB, but not TA, in muscle, spinal cord and Supplementary Fig. 4 ), indicating sufficient bioavailability of MEPB in SBMA-affected tissues, but less favorable bioavailability of TA in SBMA mice. Moreover, prior studies revealed that MEPB has greater potency than TA with respect to altering either co-regulator binding or AR activity 19, 21 . Thus, we selected MEPB for a blinded preclinical trial in SBMA mice.
MEPB demonstrates efficacy in a blinded preclinical trial in SBMA mice To further evaluate the therapeutic capacity of MEPB, we next performed a blinded, multi-dose preclinical trial of MEPB treatment in male SBMA mice. Using quantitative measures of SBMA-associated degeneration (body weight, rotarod activity, grip strength and survival) from the previous pilot study, we performed a statistical power analysis to establish the cohort numbers required for a full-scale trial (Supplementary Table 1 ). On the basis of this analysis, we assigned at least ten male NTG or SBMA mice to each treatment group. Mice were injected intra-peritoneally with low-dose (50 mg/kg) MEPB, highdose (100 mg/kg) MEPB or vehicle (1% DMSO in corn oil) three times per week starting at 4 weeks of age until the completion of the trial, at which point mice were 30 weeks of age. Low-dose and especially highdose MEPB treatment significantly augmented body weight, rotarod activity and grip strength (Fig. 4) and also qualitatively improved gait and hindlimb clasping ( Supplementary Fig. 5a ,b). Consistent with improvement in these behavioral parameters, both low-dose and high-dose MEPB treatment significantly reduced the presence of ubiquitin-positive nuclear inclusions in the spinal cord (Fig. 5a,b) , as well as degenerating myofibers in skeletal muscle (Fig. 5c,d) . Notably, both low-dose and high-dose MEPB treatment significantly reduced colocalization of NCAM/PSA-NCAM staining in SBMA mice as compared with vehicle-treated SBMA mice, decreasing these levels similar to those in NTG controls, consistent with amelioration of neurogenic atrophy (Fig. 5e,f) . Indeed, high-dose MEPB treatment prevented the loss of ChAT-positive spinal cord motor neurons, with no effect on neuron area ( Supplementary Fig. 5c,d) . Moreover, both low-dose and high-dose MEPB treatment restored the frequency of type I myofibers to levels observed in NTG control mice, whereas type II myofiber frequency remained unaffected ( Supplementary Fig. 5e,f) , further demonstrating the efficacy potential of AF2 modulation for attenuation of SBMA-associated muscle degeneration.
Finally, testicular atrophy in the SBMA mice was reversed with both low-dose and high-dose MEPB treatment (Fig. 5g) , which is not only consistent with overall improvement of the SBMA phenotype, but also underscores the selective nature of AR modulation by MEPB. Consistent with this tissue effect, the testes had the highest concentrations of MEPB in our mouse pharmacokinetic assessments, averaging 11.5 µM over the 48-h dose interval.
Neither low-dose nor high-dose MEPB treatment significantly altered the survival of SBMA mice, although a dose-dependent trend in increased survival was present (Fig. 4j) . It should be noted that (a-f) Graphs for each phenotypic assay (mean body weight in a and b, mean rotarod activity in c and d, mean grip strength in e and f are depicted using identical scales to allow comparison between NTG mice (a,c,e) and AR121Q mice (b,d,f). Mice were treated with vehicle (red squares; 1% DMSO in corn oil), low-dose MEPB (blue circles; 50 mg/kg, three times per week) or high-dose MEPB (green triangles; 100 mg/kg, three times per week). Arrows indicate last graphed data point for each treatment group due to attrition of animal numbers (<3 mice per group) from loss of >10% body weight or limb paralysis/ paresis. Data shown in a, c and e were evaluated by one-way ANOVA with repeated measures followed by Tukey post hoc analysis for all pairwise comparisons. (g-i) Statistical analysis of b, d and f up to 7 or 8 weeks of age by one-way ANOVA with repeated measures followed by Sidak's post hoc analysis for all pairwise comparisons. Mean body weight (g), mean rotarod activity (h) and mean grip strength (i) in AR121Q mice treated with vehicle (n = 10), low-dose MEPB (n = 11), or high-dose MEPB (n = 12) for time points were assayed. (g) 5 weeks: *P = 0.017, **P = 0.005, 6 weeks: *P = 0.028, 7 weeks: *P = 0.042 (50 mg/kg MEPB), *P = 0.049 (100 mg/kg MEPB), 8 weeks: *P = 0.046, **P = 0.008. (h) 7 weeks: *P = 0.0462 (50 mg/kg MEPB), *P = 0.017 (100 mg/kg MEPB). (i) 5 weeks: **P = 0.007, 7 weeks: *P = 0.045. (j) Kaplan-Meier survival estimation in treated (vehicle, low dose and high dose) NTG and AR121Q mice (log-rank test). 95% confidence intervals were used for the analysis. (k) QOL score of AR121Q mice from each treatment group from 6 to 8 weeks of age. In all panels, mice were treated with vehicle (red; 1% DMSO in corn oil), low-dose MEPB (blue; 50 mg/kg, three times per week) or high-dose MEPB (green; 100 mg/kg, three times per week). A mixed-effect model was applied with SAS software to determine statistical significance. 95% confidence intervals were used for the analysis. All graphs represent mean ± s.e.m. (f) Quantification of PSA-NCAM/NCAM colocalized regions. n = 6 fields for all NTG groups, 6, 9 and 10 fields for vehicle, 50 mg/kg, and 100 mg/kg MEPB treated AR121Q group, 2 mice for all NTG and vehicle treated AR121Q groups, 3 mice for 50 mg/kg and 100 mg/kg MEPB treated AR121Q groups, ****P ≤ 0.0001 by two-way ANOVA followed by Dunnett's post hoc analysis for pairwise comparisons between each MEPB treatment group and vehicle. (g) The area of testis were measured in n = 7, 6, 9 and 9 sections from n = 2, 2, 3 and 3 mice for vehicle-treated NTG, vehicle, 50 mg/ kg and 100 mg/kg MEPB treated AR121Q groups, respectively. Data were evaluated by one-way ANOVA followed by Dunnett's post hoc analysis for comparison between each AR121Q treatment group and NTG vehicle. *P = 0.0342. All graphs represent mean ± s.e.m.
measurement of mouse 'survival' in this trial was confounded by protocol guidelines designed to minimize morbidity in experimental animals. Mice were checked daily by our veterinary staff and recommendations to euthanize individual animals were made on the basis of a loss of 10% body weight or subjective signs of hindlimb weakness that might be severe enough to limit an animal's ability to reach the feeder. However, when other phenotypic measurements (body weight, rotarod activity, and grip strength) were compiled along with survival data to generate a QOL score, high-dose MEPB treatment significantly improved the QOL of SBMA mice (Fig. 4k) . Furthermore, MEPB treatment (low dose or high dose) did not substantially change the blood chemistry of either NTG or SBMA mice ( Supplementary  Fig. 5g-i) , and MEPB treatment (low dose or high dose) had no measurable effect on any assays of neuromuscular function in NTG control mice, suggesting that there was minimal or no MEPB-induced toxicity ( Fig. 4 and Supplementary Fig. 5b ).
Together, these findings demonstrate that AF2 modulation by MEPB in SBMA mice improves multiple primary outcomes associated with reduced QOL in patients with SBMA, such as attenuated muscle strength, diminished coordination and loss of body mass, without apparent adverse effects.
AF2 modulators do not affect normal AR signaling function, but rather promote co-repressor binding To assess the mechanism by which AF2 modulation attenuates SBMAassociated phenotypes, we performed analyses of polyQ-expanded AR activity in response to TA and MEPB ( Fig. 6 and Supplementary  Fig. 6 ). Neither TA nor MEPB treatment reduced steady-state levels of polyQ-expanded AR protein in stably transfected motor neuron (MN1) cells or transiently transfected HEK293T cells ( Supplementary  Fig. 6a-e) , indicating that reduced SBMA-associated toxicity resulting from TA and MEPB treatment is not simply a result of enhanced degradation of the AR. In addition, the presence of high-molecular weight, multimeric AR complexes and aggregates were unchanged in response to TA and MEPB treatment in HEK293T cells ( Supplementary  Fig. 6e,f) . Consistent with these observations, MEPB treatment did not statistically significantly change the expression levels of endogenous mouse AR or transgenic human AR in the muscle and spinal cords of AR121Q mice (Supplementary Fig. 7) . Similarly, neither MEPB nor TA treatment changed the expression of transgenic AR in Drosophila (Supplementary Fig. 2d,e) , suggesting that TA-and MEPB-mediated attenuation of toxicity occurs independently of AR aggregation. Moreover, neither MEPB nor TA treatment altered DHTdependent nuclear translocation of polyQ-expanded AR in HEK293T cells and Drosophila (Fig. 6a,b) . A dual luciferase reporter assay revealed that the transactivational capacity of polyQ-expanded AR was not significantly altered by MEPB treatment, although reduced transcriptional activity was present in cells treated with high concentrations (100 µM) of either TA or bicalutamide (Fig. 6c) . Finally, we selected eight AR-responsive genes that were expressed in motor neurons (Igfbp5, Mt2, Sgk1, Trib1, Camkk2, Tsc22d3, Plk3r3 and AR) and assessed the effect of MEPB in response to ligand-dependent changes in transcription in MN1 cells that stably express human AR (MN1-AR24Q cells). We confirmed statistically significant ligand-dependent changes in transcription for seven of the eight target genes, but found no effect for MEPB (Fig. 6d) . These results indicate that, although the AR signaling pathway remains intact, AF2 modulation by SARMs selectively alters AR activity, reducing the toxicity associated with polyQ-expanded AR, but leaving other aspects of AR responsiveness intact. Indeed, the reversal of testicular atrophy in the SBMA mice following treatment with MEPB is consistent with this conclusion.
Because the AR has been well characterized to repress as well as activate transcription of its target genes, and these repressor/activator activities are dependent on binding of a specific complement of coactivators and co-repressors to the AF2 domain 10 , we hypothesized that SARM treatment may specifically promote recruitment of co-repressors to the AF2 domain rather than block coactivator binding. This would potentially lead to repression of selected target genes driving SBMAassociated toxicity while allowing transcriptional activation of other target genes. To determine whether association between the AR LBD and steroid receptor co-repressors is augmented in response to AF2 modulation by TA or MEPB, we performed a mammalian two-hybrid assay, in which increased association between the AR LBD and a given co-regulator drives luciferase reporter activity. Consistent with our hypothesis, binding between the AR LBD and nuclear receptor co-repressor-1 (NCoR) was specifically increased by TA and MEPB treatment, whereas binding of silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) was unchanged (Fig. 6e) , suggesting that modulation of the AF2 domain by TA and MEPB occurs by a selective and precisely controlled mechanism.
DISCUSSION
Recent advances in prostate cancer research have led to the discovery of many SARM compounds that specifically bind to and modulate co-regulator binding to the AR AF2 domain [17] [18] [19] [20] [21] [22] . Notably, it has been suggested that a reciprocal relationship between prostate cancer and SBMA is mediated by polyQ length, given that prostate cancer risk appears to be elevated in individuals whose AR gene contains fewer than ten CAG repeats 28 . Increased transactivational activity of the AR is also inversely correlated with CAG repeat length 29, 30 , and polyQ expansion has been suggested to augment intrinsic disorder in the N-terminal domain, reducing coactivator binding to the AR LBD through an unknown mechanism 31, 32 . To avoid the proliferative effects of increased AR transactivation, investigators have sought compounds that reduce coactivator binding or recruit co-repressor binding to the AF2 domain for prostate cancer therapy. The seminal discovery of the BF3 regulatory pocket as an allosteric regulator of the AF2 domain was an unexpected revelation in the search for such drugs 19 . The development of several compounds that specifically target the BF3 pocket have since been reported [20] [21] [22] .
A recent report demonstrated the importance of the BF3 domain in prostate cancer and the role that BF3 modulation may have in therapeutic treatment 33 . Specifically, ectopic expression of the cochaperone Bag-1L in the prostate secretory epithelium may be associated with tumorigenesis by stimulating AR activation via interaction between a duplicated GARRPR hexapeptide motif in Bag-1L and the AR BF3 binding pocket. Notably, the binding of LXXLL-bearing coactivators to the AF2 domain was inhibited by Bag-1L binding to the BF3 pocket, further demonstrating the allosteric regulation that BF3 imparts on the AF2 domain. Moreover, BF3-Bag-1L binding was inhibited by the MEPB analog 2-((2-(2,6-dimethylphenoxy)ethyl)thi o)-1H-benzimidazole (compound 49 or CPD49) 20, 33 , suggesting that modulation of the interaction between the AR and Bag-1L by CPD49 may provide a promising approach to mitigate the oncogenic program initiated by androgen signaling in prostate cancer.
We previously showed that coactivator binding to the AF2 domain is required for polyQ-expanded AR toxicity in Drosophila 8 . Despite the apparent reciprocal relationship between prostate cancer and SBMA, we reasoned that targeting the BH3 interaction surface to modulate co-regulator binding to the AF2 domain may represent a common strategy for treatment of both SBMA and prostate cancer.
Thus, we initiated a Drosophila-based screen to determine whether any previously described BF3-binding compounds may be advantageous for the treatment of SBMA. As expected, several compounds either had no effect on, or even exacerbated, SBMA toxicity (data not shown), suggesting that some compounds may be more effective in the treatment of prostate cancer, whereas others may be more effective for SBMA. Nevertheless, two promising compounds (TA and MEPB) emerged that ameliorated polyQ-expanded AR toxicity in flies and became candidate therapeutics for a preclinical trial in a mammalian model of SBMA.
TA is a well-known and well-studied compound belonging to the nonsteroidal anti-inflammatory drug family of small molecules [34] [35] [36] [37] . Although it has been approved for treatment of migraines in the UK by the National Health Service and is available as a general analgesic Third instar larvae expressing GFP-AR52Q in motor neurons were dissected and stained for nuclear membrane (lamin, red) and DAPI (blue). Scale bar represents 10 µm. Representative images are shown from one independent experiment. (c) AR transcriptional activity reporter assay. HEK293T cells were transiently transfected with AR24Q (blue) or AR65Q (red) in addition to an ARE-luciferase reporter before treatment with Bic, TA or MEPB. Four independent biological replicates were performed on different days with three sample replicates for each treatment group. Data were evaluated by twoway ANOVA followed by Dunnett's post hoc analysis for pairwise comparisons between each treatment group and the DHT only group. ***P = 0.001 for 100 µM Bic AR24Q and 100 µM Bic AR65Q, *P = 0.017 for 100 µM TA AR24Q and 100 µM TA AR65Q. (d) Digital PCR assay to access the effect of MEPB on AR target gene expression. Data were evaluated by ordinary one-way ANOVA followed by Tukey's post hoc analysis for all pairwise comparisons. *P = 0.0120 versus −DHT/-MEPB, **P = 0.0068 for AR versus −DHT/-MEPB, ***P = 0.0003 (+DHT) versus −DHT/-MEPB and ***P = 0.0001 (+DHT/ +MEPB) versus −DHT/-MEPB for Igfbp5, ***P = 0.0001 versus −DHT/-MEPB for Trib1, ****P ≤ 0.0001 versus −DHT/-MEPB. (e) Mammalian twohybrid assay to assess binding between the AR LBD and the corepressors NCoR or SMRT in the presence of TA (blue) or MEPB (red). Two independent biological replicates were performed on different days with three sample replicates for each treatment group. Data were evaluated by two-way ANOVA followed by Dunnett's post hoc analysis for pairwise comparisons between each treatment group and the DHT + DMSO group. ***P = 0.001 for ethanol, 10 µM TA, 1 µM MEPB and 10 µM MEPB, **P = 0.002 for 1 µM TA, **P = 0.007 for 100 µM TA. All graphs represent mean ± s.e.m.
for humans and animals in several countries in Europe, Latin America and Asia, it has not been approved for any use in the US. This compound was found to have an unfavorable murine pharmacokinetic profile, that is, low bioavailability in mouse brain, spinal cord and muscle, and had no significant effect in a pilot trial in AR121Q mice. Thus, TA was not subsequently pursued in this detailed proof of concept study. MEPB was first described by a study that used virtual screening for BF3-binding compounds 21 . X-ray crystallography revealed that MEPB specifically binds the BF3 pocket of the AR, where the benzimidazole moiety of MEPB is oriented toward the interior of the BF3 pocket and is stabilized by strong hydrophobic interactions with Pro723, Phe673, Tyr834 and an arene-arene conjugation between a benzene ring of MEPB and Phe826. MEPB was shown unequivocally to bind to the BF3 domain and, as a consequence, modulate AF2 binding to co-regulators. MEPB had comparatively favorable bioavailability in mouse brain, spinal cord and muscle and, after showing a beneficial effect in a pilot trial in SBMA mice, was selected for detailed evaluation. In a blinded, multi-dose preclinical trial in male SBMA mice, MEPB treatment was found to significantly augment body weight, reduce hindlimb clasping, and improve rotarod activity, grip strength, gait and QOL score. Although MEPB did not significantly extend AR121Q survival, this aspect of the pre-clinical trial was confounded by protocol guidelines that were designed to minimize morbidity in experimental animals. There were no spontaneous deaths; instead, all mouse deaths represented euthanization of mice after a loss of 10% body weight or the development of substantial weakness. Nevertheless, we do not believe that lifespan extension should be used as the primary criterion for judging the efficacy of a pre-clinical therapeutic for SBMA. Men with SBMA do not exhibit a shortened lifespan. Rather, they experience substantial progressive morbidity resulting from weakness that impairs bulbar functions and ambulation, and feminization (testicular atrophy and gynecomastia). In our mouse pre-clinical trial, MEPB treatment resulted in significant improvement in phenotypic measurements (body weight, rotarod activity and grip strength). These data, compiled with survival data, generated a QOL score that was significantly improved in MEPBtreated SBMA mice. Consistent with improvement in the behavioral phenotype, MEPB treatment rescued motor neuron loss and neurogenic atrophy. Finally, MEPB treatment was found to reverse testicular atrophy in the SBMA mice, a finding that underscores the selective activity of MEPB. Prior in vitro analyses found that MEPB binding to BF3 enhances AF2 interaction with co-regulators bearing an extended LXXLL motif (termed the corepressor nuclear receptor box), such as that found in the co-repressor NCoR 38, 39 . This observation is consistent with our observation that NCoR was recruited to the AR LBD by MEPB, and suggests that MEPB may relieve polyQ-expanded ARmediated toxicity by promoting the binding of co-repressors to the AF2 domain.
Taken together, our results provide considerable evidence for the utility of AR AF2 domain modulation by BF3-binding compounds as a method for SBMA therapy. Subtle modulation of co-regulator binding, and thus AR functional activity, rather than ablation of the entire androgen signaling pathway, may provide therapeutic relief of neurodegenerative symptoms in patients with SBMA. Such a targeted approach may reduce or potentially even reverse the adverse effects of androgen insensitivity and improve the QOL of patients with SBMA.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Study design. The objective of this study was to determine whether modulation of the AR AF2 domain by small molecules that specifically bind to the BF3 regulatory pocket would be a practicable therapy for improving the QOL of patients with SBMA. To this end, we screened several BF3-specific compounds in Drosophila; performed a pilot preclinical study of the top two candidate compounds; performed an extensive, multidose preclinical study of the lead compound; and determined the mechanism of action of these compounds in cell culture studies. Drosophila NMJ staining and analysis was performed in a blinded manner, whereby treated larvae were coded by an independent investigator. Treatment groups were not uncoded until analyses were completed. Both preclinical trials were performed in a blinded manner, whereby drugs (that is, vehicle, TA, and/or MEPB) were assigned a specific code by an independent investigator. Treatment groups remained blinded until data collection and analysis were complete. Drug dose and animal numbers were determined empirically for the pilot preclinical study. The data acquired from this study were used in a power analysis to estimate the number of animals required for the preclinical study. Animal endpoints were reached when a mouse exhibited hindlimb paralysis/paresis or greater than 10% loss of bodyweight, at which point the animal was humanely euthanized. Because the yield of AR121Q-positive male mice was generally low throughout our studies, randomization was not possible. Mice were entered into treatment groups as they became available and were followed longitudinally. Replicate number and statistical tests for each data set are provided in the figure legends.
Reagents. For fly and cell culture experiments, TA (Sigma Aldrich), MEPB (Specs), bicalutamide (3B Scientific Corporation), ibuprofen (Sigma Aldrich), or dimethylcurcumin (Cayman Chemical) were resuspended in DMSO (Sigma Aldrich), whereas DHT (Steraloids) was dissolved in ethanol, before addition to fly food or culture media. All cell culture experiments were performed in media containing 10% charcoal-dextran stripped serum (Hyclone) to remove exogenous steroid hormones. For preclinical and pharmacokinetic mouse studies, TA and MEPB were dissolved in either a 10 mg/ml (low dose) or 20 mg/ml (high dose) solution of corn oil containing 1% DMSO at 37 °C for approximately 12 h, filtered (0.22-µm filter), and stored at 4 °C until injection.
Molecular modeling. BF3-unbound AR LBD (pdb1T7R) in complex with an FXXLF motif was modeled using PyMOL software. BF3 residues (I690, F691, P723, G724, N727, F826, E829, N833, E837 and R840) were highlighted green, charge clamp residues of the AF2 domain (K720, M734, M894 and E897) were highlighted red, and a synthetic FXXLF (FESLF) motif was highlighted blue. MEPB modeling was performed in the same manner using pdb2YLO. TA modeling was performed in a similar manner using pdb2PIX, whereby flufenamic acid was removed and TA was added according the lowest predicted energy conformation using SwissDock software.
Fly stocks and phenotypic characterization. UAS-AR52Q, UAS-AR52Q-K720A, and UAS-AR66Q-E897K fly stocks were generated as previously described 8 . Fly stocks were crossed to various GAL4 driver lines (ELAV-GAL4 for pan-neuronal, OK371-GAL4 for motor neuron, GMR-GAL4 for eye) to induce expression of the AR transgene in a tissue-specific manner in fly vials containing fly food with either vehicle (1% ethanol ± 0.1% DMSO) or drugs. Upon the presence of progeny, parental flies were removed, and F1 flies were scored for phenotypic analysis. Viability was determined as previously described 40 . Briefly, the population frequency of adult F1 SBMA flies (ELAV>UAS-AR52Q or OK371>UAS-AR52Q) and control flies (GAL4-ELAV; CyO-GFP) were determined by the presence or absence of the CyO phenotypic marker. At least three independent biological replicates (F0 crosses) were performed with new drug/food preparations for each treatment group, and a total of at least 50 flies were scored for each treatment group. To determine locomotor activity of SBMA flies, adult F1 flies (OK371>UAS-AR52Q) reared on food containing vehicle or drug were allowed to walk for 90 s in one well of a 12-well tissue culture plate while video was recorded using a Leica M205C stereomicroscope and Leica DFC320 digital camera. Videos were recorded for at least 15 flies per treatment group. Tracing of fly movement and analysis of displacement and velocity were performed using ImageJ software. Preparation and staining of larval neuromuscular junctions and ventral ganglions were performed as previously described 8 .
Generation of AR121Q transgenic mice and surgical castration. Human AR cDNA containing 121 CAG/CAA alternating repeats was subcloned into the pCAGGS vector. An 11.5-kb fragment containing the pCAGGS promoter and AR cDNA was released by ApaL1 digestion, purified by QIAEXII (Qiagen), and injected into FVB pronuclei, which were transferred into female FVB recipients. Founders were screened by DNA genotyping of tail biopsies. Fluorescence in situ hybridization analysis was performed on lung tissue to confirm transgene insertion. Out of 15 founders, one line was viable, demonstrated germline transmission, and expressed levels of hAR protein comparable with that of endogenous mouse AR. Therefore, the phenotype of this line was extensively characterized. Mice were maintained on a purebred FVB background for all studies.
Castration was performed according to USDA guidelines for aseptic technique in animal survival surgery and oversight was provided by veterinary staff at St. Jude Children's Research Hospital. Briefly, mice were anesthetized by isoflurane exposure, and the surgical site was prepared by shaving and disinfection. A 10-mm incision was made along the scrotal midline, and the testes were removed using forceps. The connection between the testes and vas deferens, as well the associated blood vessels, were cauterized by hot forceps. Incisions were closed using tissue glue, and preemptive analgesia (0.2 mg/kg meloxicam) was administered. Mice were bred and maintained in accordance with the guidelines set forth by the National Institutes of Health Guide for the Care and Use of Laboratory Animals, published by the US Public Health Service. All experimental protocols were approved by the Institutional Animal Care and Use Committee at St. Jude Children's Research Hospital.
Preclinical trial design in AR121Q mice. To determine the efficacy of TA and/ or MEPB in a mouse model of SBMA, we first performed a pilot study. Five mice were assigned to each drug treatment group: 50 mg/kg TA, 50 mg/kg MEPB, or vehicle (1% DMSO in corn oil). Drug identities were coded to ensure investigator blinding, and drugs were administered three times per week (Monday, Wednesday, and Friday) by intraperitoneal injection from 3 to 8 weeks of age. At 8 weeks, all mice were sacrificed and tissues were collected for pathologic analysis. To fully characterize the efficacy of MEPB in SBMA mice, a multi-dose preclinical trial was performed. A power analysis (Supplementary Table 1 ) was performed based on the pilot study data to determine the adequate number of mice required for 80% power. At least ten mice were assigned to each drug treatment group: 50 mg/kg MEPB, 100 mg/kg MEPB, and vehicle (1% DMSO in corn oil). Drug identities were coded to ensure investigator blinding, and drugs were administered three times per week (Monday, Wednesday and Friday) by intraperitoneal injections from 4 weeks until 30 weeks of age.
AR121Q mouse phenotypic characterization. Body weight, rotarod activity and grip strength data were collected weekly. Footprint analysis and clasping phenotype were assessed at 7 and 8 weeks of age. Body weight was measured using a standard laboratory scale (Fisher Scientific). Rotarod activity analysis was performed on an accelerating rotarod apparatus (IITC Life Science) using a 2-d, weekly protocol. Mice were trained on the first day with one session set at 4 rpm for 5 min. The following day, mice were placed on the apparatus, rotation speed was set to accelerate from 4-40 rpm at a rate of 0.1 rpm/s, and the latency to fall was recorded for four separate trials per mouse. Mice were given a 15-min rest period between each trial. Grip strength was measured using a grip strength meter (Bioseb). Grip strength was measured as grams of force in six repeated measurements for forepaws and hindpaws of each animal. To perform gait/footprint analysis, the forepaws and hindpaws of each animal were dipped in red and blue, respectively, water-soluble, non-toxic paint. The animal was then placed in a 70-cm long tunnel lined on the bottom with Whatman filter paper, the entrance was sealed, and the animal was allowed to walk through one time. Footprints were scanned and analyzed with Image J for stride length and forepaw/hindpaw overlap 41 . To determine clasping phenotype, mice were recorded using an Apple iPod camera (iOS version 6.1.6) for approximately 60 s and still frames were extracted using ImageJ. AR121Q mouse pathologic assessment. A separate cohort of five mice per treatment group was generated for pathologic and biochemical analysis. Mice were anesthetized by isoflurane inhalation and transcardially perfused with either PBS for frozen tissue samples or 10% formalin for fixed tissue samples. Selected tissues (brain, spinal cord, gastrocnemius/soleus muscle, testes and liver) were dissected and either snap-frozen in liquid nitrogen or processed for paraffin embedding/sectioning. Tissue sections were stained with hematoxylin and eosin, toluidine blue, or Gomori trichrome to ascertain overall morphology and pathologic changes. To determine AR staining and colocalization patterns, tissue sections were stained with anti-AR (EPR1535, Abcam), anti-polyQ (5TF1-1C2, EMD Millipore), or anti-ubiquitin (Dako) primary antibodies. To quantify type I and type II myofibers, hindlimb tissue sections were stained with myosin heavy chain-slow twitch and myosin heavy chain-fast twitch antibodies (Leica Biosystems), respectively. For the purposes of counting ChAT-positive neurons, three stepped sections separated by 50 µm were analyzed for the cervical, thoracic, and lumbosacral areas of spinal cords. The slides contained three to six tissue sections at each level and were labeled with an anti-ChAT antibody (EMD Millipore). Following primary antibody staining, slides were incubated with rabbit anti-IgG1 + IgG2a + IgG3 secondary antibody (M204-3, Abcam) if needed, and staining visualized with the OmniMap rabbit detection system (Roche). All slides were digitally scanned at scalable magnifications up to 20× (objective lens) using an Aperio XT Slide Scanner (Leica Biosystems). Whole slide images were imported into the Halo software program (Indica Labs) and positive staining was quantified by an area quantification algorithm. For spinal cord motor neuron quantification, static images were made at a 2× magnification with ImageScope (Leica Biosystems) and the number of ChAT-positive neurons located within the anterior horn were counted with FIJI software 42 .
Pharmacokinetics. MEPB and TA concentrations in plasma, liver, muscle, testes, brain, and spinal cord of male FVB/NJ mice were measured at multiple time points (5 min to 48 h) after a single intraperitoneal injection of either 100 mg/kg body weight MEPB or 50 mg/kg body weight TA. A 25-µl aliquot of MEPB spiked with 100 ng/ml internal standard SLV320 (Tocris Biosciences) were extracted from plasma and tissue homogenate samples with 600 µl methyl tertbutyl ether. After 5 min of vortexing, samples were centrifuged at 10,000 rpm for 5 min, the organic layer was then transferred to a glass vial and dried in a CentriVap Console (Labconco) at 35 °C for 25 min. The dried extracts were then reconstituted with 400 µl methanol, and an aliquot of 3 µl was injected onto the chromatographic system. For TA, a 25-µl aliquot of sample was spiked with 1000 ng/ml internal standard diclofenac (Alfa Aesar), and extracted from plasma and tissue homogenate samples with 100 µl acetonitrile. After vortexing for 5 min, samples underwent centrifugation at 10,000 rpm for 5 min, and an aliquot of 5 µl supernatant was injected into the chromatographic system. All chemicals were HPLC grade or higher and were obtained from Fisher Scientific (Fair Lawn) unless otherwise specified. Quantitation of MEPB and TA was performed using an API 4000 mass spectrometer (SCIEX) equipped with a Prominence UltraFast Liquid Chromatograph (UFLCXR) system (Shimadzu). Chromatographic separation was achieved with a Phenomenex Luna C18 column (3 µm, 100 A ° 50 × 2.00 mm) by using mobile phases consisting of 0.1% formic acid in water (A) and acetonitrile (B). Mass spectrometric analysis was performed with the turbo ion spray in positive ionization mode. All MS data were acquired using Analyst 1.5.2 software and processed using MultiQuant 2.1.1 software (SCIEX).
For all matrices (plasma, liver, muscle, testes, brain, and spinal cord), the lower limit of quantification (LLOQ) of MEPB was 6.18 nM with a calibration range of 6.18 ng/ml to 247 nM. However, due to dilution during homogenization, the effective LLOQ was 37.1 nM for solid tissues. The LLOQ of TA was 19.1 nM for plasma and 229 nM for tissues. Assays were found to be linear and reproducible with a correlation coefficient (R) > 0.99. The MEPB and TA concentration-time (Ct) data for plasma, liver, muscle, testes, brain, and spinal cord were grouped by mouse and analyzed using a two-stage, semi-physiologic, nonlinear mixed effects approach with maximum likelihood expectation maximization in ADAPT 5 (ref. 43) . For data below the LLOQ, Beal's M3 method was applied 44 . First, compartmental models were fit to plasma data-one-and two-compartment models were fit to MEPB and TA plasma Ct data respectively, with first order absorption. Population mean PK parameters with inter-mouse variability and post hoc individual mouse parameters were estimated. The resulting individual mouse plasma parameters were inputted into the semi-physiological tissue PK model. Briefly, the tissue Ct data were well described with a rapid equilibrium, perfusion-limited model, using specific mouse tissue blood flows fixed to literature values [45] [46] [47] [48] [49] . The population mean and inter-mouse variability of the tissue to plasma partition coefficients (Kp,tissue) were estimated, along with proportional residual error.
Monte Carlo simulations (n = 1,000 subjects) using the population mean PK parameters and variances for MEPB and TA were conducted using ADAPT 5, with a 100-step 48-h Ct profile simulated for each compound, tissue, and theoretical subject. Each profile was subjected to noncompartmental analysis (NCA) using standard formulae 50 with the package 'PKNCA' 51 in R 52 . Estimated parameters from the simulated data included maximum concentration (Cmax), time of Cmax (Tmax), and the area under the Ct curve from 0 to the last time point of 48 h (AUClast). The terminal phase was defined as at least three time points at the end of the Ct profile and an elimination rate constant (Kel) was also estimated using an unweighted log-linear regression of the terminal phase. The terminal elimination half-life (T1/2) was estimated as ln (2)/Kel, and the AUC from time 0 to infinity (AUCinf) was estimated as the AUC to the last time point (AUClast) + predicted last concentration/Kel. Each NCA parameter was summarized using the median and 90% prediction interval, and tabulated for presentation.
Immunoblotting and immunofluorescence.
Lysates from mouse tissues were prepared by grinding snap-frozen tissues on dry ice with a pestle until pulverized into a fine powder, resuspending in ice-cold RIPA (1% Triton-X, 0.1% sodium deoxycholate, and 0.1% SDS in Tris/NaCl) buffer, briefly sonicating, and centrifuging at 14,000 g for 20 min. Drosophila lysates were prepared as previously described 8 . Cell lysates were prepared by scraping transfected (mycoplasma -free) HEK293T cells (ATCC) or MN1 (first described in ref. 53 , gift from K. Fischbeck, US National Institutes of Health) cells into room temperature (20-25 °C) PBS, centrifuging at 400 g for 5 min, and resuspending pellets in ice-cold RIPA buffer, briefly sonicating, and centrifuging at 14,000 g for 20 min. Supernatants were then collected, and protein levels were measured and adjusted using Bradford analysis. Proteins were separated on 4% to 20% or 8% Tris-glycine gels and transferred overnight at 4 °C onto PVDF membranes. Membranes were stained with REVERT total protein stain (Li-Cor) and immunoblotted using anti-AR (H280 or N20 [Santa Cruz], D6F11 [Cell Signaling Technology], or EPR1535 (2) [Abcam]), anti-tubulin (Sigma Aldrich), anti-GAPDH (Cell Signaling Technology), or anti-β-actin (Santa Cruz) primary antibodies, followed by anti-mouse or anti-rabbit HRP-linked secondary antibodies (Cell Signaling Technology) and ECL detection (ThermoFisher Scientific). Filter trap assay for aggregation was performed by resuspending cell lysates in a 10% SDS buffer to achieve a final 2% SDS concentration, heating for 5 min at 95 °C, and applying to a 0.22-µm cellulose acetate membrane (GE Healthcare Life Sciences) with a vacuum dot blot apparatus (Schleicher and Schuell). Membranes were washed three times with 0.1% SDS and blotted with anti-FLAG (M2, Sigma Aldrich), followed by anti-mouse HRP-lined secondary antibody (Cell Signaling Technology) and ECL detection (ThermoFisher Scientific). For immunofluorescence experiments in Drosophila, UAS-AR flies were crossed to OK371-GAL4 flies at 25 °C on food containing either 1 mM DHT (Steraloids) or 1% ethanol together with indicated drug. Third instar larvae were heat killed, dissected in PBS, and fixed with 4% PFA for 20 min. Primary antibody staining (anti-AR D6F11, Cell Signaling Technolofy) was performed at 4 °C overnight followed by staining with the appropriate Alexa Fluor-conjugated secondary antibody (ThermoFisher Scientific) at 20-25 °C for 4 h. After staining, pelts were mounted in Fluoromount-G (SouthernBiotech). For immunofluorescence experiments in HEK293T cells (ATCC) or MN1 cells, HEK293T cells were transiently transfected with AR65Q for 48 h in culture media devoid of steroid hormones and treated for 24 h with vehicle, 10 nM DHT, or 10 nM DHT + 10 µM bicalutamide (Bic), TA, or MEPB before being fixed in 4% formaldehyde in PBS for 10 min at 20-25 °C. Thereafter, cells were permeabilized with 0.5% Triton-X 100 and incubated with an anti-AR antibody (D6F11, Cell Signaling Technology) for 1 h, followed by incubation for 2 h at 20-25 °C with the appropriate Alexa Fluor-conjugated secondary antibody (ThermoFisher Scientific). Cells were then washed, stained with DAPI, and visualized on an inverted widefield fluorescence microscope (Leica DMI3000b) using a 63× objective.
For immunofluorescence experiments in mice, deparaffinized and rehydrated cross-sections of spinal cord and hindlimb muscle were permeabilized in 2% Triton-X 100, treated with TrueBlack autofluorescence quencher (Biotium), and blocked in PBS with 4% BSA and 2% NGS. Sections were incubated overnight at 4 °C with anti-NCAM (Proteintech), anti-PSA-NCAM (EMD Millipore), anti-ubiquitin (Abcam), or anti-polyQ (EMD Millipore) antibodies, followed by incubation for 2 h (20-25 °C) with the appropriate Alexa Fluor-conjugated secondary antibodies (ThermoFisher Scientific). Sections were mounted with ProLong Gold Antifade Mountant with DAPI (ThermoFisher Scientific) and allowed to dry for at least 24 h at (20-25 °C) before imaging on a Leica TCS SP8 STED 3X confocal microscope (Leica Biosystems for ubiquitin-polyQ colocalization or Leica DMI8 Widefield microscope for NCAM) with 40× objective and LASX software (Leica).
NCAM imaging and analysis. One image was acquired in a region of three to four slices where bright punctate NCAM and PSA-NCAM could be seen within the muscle fibers. If no punctate regions greater than that of autofluorescence intensity in either channel could be seen, a representative field without punctate signal was taken for that muscle slice. Imaging and analysis was performed for two mice from each of the following conditions: untreated NTG, untreated SBMA, NTG treated with 50 mg/kg MEPB, and NTG treated with 100 mg/kg MEPB. Three mice each were analyzed from each of the following conditions: SBMA treated with 50 mg/kg MEPB and SBMA treated with 100 mg/kg MEPB. The same images were subjected to colocalization analysis with LASX software. For each image, the background out-of-focus light was subtracted out and the remaining white detail was enhanced to make the punctate regions more easily recognizable by the program. Following processing, an intensity-based mask was created for each channel, recognizing the regions where the signal was above that of tissue autofluorescence. These masks were then dilated and smoothed to combine nearby punctate regions. Using a binary ' AND' operand, the number of overlapping regions larger than 5 pixels that had signal in both masks was calculated. Two-way ANOVA with Dunnett's multiple comparisons test was performed using GraphPad Prism version 6. P < 0.05 was considered significant.
Luciferase reporter assays.
To determine AR-dependent transcriptional activity, HEK293T cells were transiently transfected in culture media containing 10% charcoal-dextran stripped serum with ARE-firefly luciferase and CMV-Renilla luciferase (Cignal ARE Reporter Assay Kit, Qiagen), in addition to either FLAG-AR24Q or FLAG-AR65Q (gift from M. Pennuto, University of Trento). Following 24 h of transfection, cells were washed and treated with vehicle, bicalutamide, TA, or MEPB for 24 h. Firefly and Renilla luciferase substrates (Dual-Luciferase Reporter Assay, Promega) were added, and luciferase activity was measured using a microplate spectrophotometer (BioTek). Mammalian two-hybrid assays were performed by transiently transfecting HEK293T cells with pG5Luc firefly luciferase reporter (Checkmate Mammalian Two-Hybrid kit, Promega), CMV-Renilla luciferase (Cignal ARE Reporter Assay Kit, Qiagen), and GAL4 DBD-AR LBD (gift from E. Wilson, University of North Carolina), in addition to either VP16 empty vector, VP16-NCoR, or VP16-SMRT (gifts from V. Bardwell, University of Minnesota) for 24 h. Cells were then washed and treated with vehicle, TA, or MEPB for 24 h. Renilla and firefly luciferase were quantified using Dual-Luciferase Reporter Assay (Promega) and a microplate spectrophotometer (BioTek).
Droplet digital PCR. The QX200 droplet digital PCR (ddPCR) system (BioRad) was used to measure gene expression levels in 20 µl emulsion PCR reactions that contain 20,000 droplets. Total RNAs were first treated with DNase (ThermoFisher Scientific, AM1907) to remove genomic DNA, and 5 ng of treated RNA was used in each assay. ddPCR assay consisted of the following components: 1× one-step RT-ddPCR mix for probes (Bio-Rad, 1864021), forward primer (900 nM), reverse primer (900 nM), probe (FAM or VIC, 250 nM), nuclease-free water, and 5 ng RNA. All primers and probes were purchased from ThermoFisher Scientific. Droplets were generated in the droplet generator (Bio-Rad) and PCR was performed in a C1000 Touch thermal cycler (Bio-Rad) according to the manufacturer's recommendation. After PCR, readout of positive versus negative droplets was performed using the QX200 droplet reader (Bio-Rad) and calculated by QuantaSoft software version 1.7.4.0917 (Bio-Rad).
Statistical analyses. Significant changes in Drosophila population frequencies (that is, viability) were determined by Chi square analysis. Survival of SBMA mice was determined by Kaplan-Meier estimation, and comparisons between survival curves were made with the log-rank (that is, Mantel-Cox) test. All other data, except power analysis and QOL score, were analyzed by one-way or twoway ANOVA and either Tukey's or Dunnett's post hoc analysis, where appropriate, with Prism software (version 6.0, GraphPad). Power analysis was performed to determine sample size requirements to achieve 80% power using SAS software (SAS Institute). QOL scores were determined by averaging the change from baseline measurements for each behavioral phenotype (body weight, grip strength, and rotarod activity). A score of zero was applied at each time point for any animal that could not complete the task due to hindlimb paralysis or that had been euthanized. A mixed effect model was applied using SAS software to determine statistical significance.
Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.
Data availability. The data that support the findings of this study are available from the corresponding author upon reasonable request.
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Experimental design 1. Sample size
Describe how sample size was determined.
For the multi-dose preclinical trial, a power analysis was performed based on the pilot study data to determine the adequate number of mice required for 80% power (Supplementary Table 1 ). For all other experiments, no tests were used to pre-specify effect size.
Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
Yes, the experimental findings were found to be reproducible with biological replicates as indicated for each individual experiment.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For mouse experiments, randomization was not possible because the yield of AR121Q-positive male mice was generally low throughout our studies. Mice were entered into treatment groups as they became available and were followed longitudinally. No randomization was performed for Drosophila experiments.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For mouse experiments and Drosophila neuromuscular junction experiments, drug identities were coded to ensure investigator blinding.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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